Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYBB | P04839 | 1/20 | 0.42 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.42 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597649 | 0.87 | SCN9A (0.53) | SCN9AUSP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3610026 | 0.85 | SCN9A (0.51) | SCN9AUSP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3599625 | 0.85 | SCN9A (0.51) | SCN9AUSP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3604813 | 0.84 | USP30 (0.59) | SCN9AUSP30SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3609803 | 0.82 | USP30 (0.52) | SCN9AUSP30MEN1KMT2ASTS | |
| SCHEMBL3606991 | 0.82 | SCN9A (0.49) | SCN9AUSP30MEN1KMT2ASMARCA2 | |
| SCHEMBL3605594 | 0.82 | USP30 (0.61) | SCN9AUSP30MAPTSTSPOLB | |
| SCHEMBL3608564 | 0.82 | USP30 (0.54) | SCN9AUSP30MEN1KMT2ASMARCA2 | |
| SCHEMBL31248191 | 0.80 | USP30 (0.46) | SCN9AUSP30MEN1KMT2ASMARCA2 | |
| SCHEMBL31248211 | 0.80 | USP30 (0.46) | SCN9AUSP30MEN1KMT2ASMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2039695-A1 | BICYCLIC HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004249-A1 | Bicyclic heterocyclic compound and use thereof | HTR2C, HTR5A, HTR2A | SCN9A 1132/4885USP30 4815/4885MEN1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.